|
    VXRT U.S.: Nasdaq
    VXRTUS
    After Hours
    Back To Top
    Last Updated: May 7, 2021 7:59 p.m. EDT Delayed quote

    $ 7.15

    -0.05 -0.69%
    After Hours Volume: 177.52K
    Close Chg Chg %
    $7.20 0.27 3.90%
    Advanced Charting
    • $
    • %
    • Vol
    Volume: 11.76M 65 Day Avg: 18.4M
    64% vs Avg
    6.70 Day Range 7.46
    2.23 52 Week Range 24.90

    Your Watchlists

    Customize eLesor

    Have Watchlists? Log in to see them here or sign up to get started.

    Symbol
    Company
    Price
    Chg/Chg %
    No Items in Watchlist

    There are currently no items in this Watchlist.

    Uh oh

    Something went wrong while loading Watchlist.

    Recently Viewed Tickers

    No Recent Tickers

    Visit a quote page and your recently viewed tickers will be displayed here.

    VXRT Overview

    Performance

    5 Day
    • -33.21%
    1 Month
    • 30.20%
    3 Month
    • -6.49%
    YTD
    • 26.09%
    1 Year
    • 182.35%

    Analyst Ratings

    • Sell
    • Under
    • Hold
    • Over
    • Buy
    Number of Ratings 2 Full Ratings

    Recent News

    • eLesor
    • Dow Jones

    Vaxart stock price target cut to $13 from $16 at B. Riley

    Read full story

    Does Valuation Matter in a Short Squeeze?

    Read full story

    Lifted by a Short Squeeze, Vaxart Stock Sinks on Lackluster Vaccine News

    Vaxart shares fall 42% on disclosure of early-stage results from COVID-19 vaccine study

    Vaxart's stock rallies 15% after it gets clearance to begin human trials of COVID-19 vaccine candidate

    Vaxart started at buy with $22 stock price target at B. Riley FBR

    Emergent BioSolutions inks coronavirus vaccine manufacturing deal with J&J

    Vaxart shares skyrocket on news its COVID-19 vaccine candidate to be part of 'Operation Warp Speed'

    Vaxart COVID-19 vaccine candidate selected for U.S. govt's 'operation warp speed' program

    Read full story

    NortonLifeLock and Bancorp See Activist Actions

    Read full story

    These 23 companies are working on coronavirus treatments or vaccines — here’s where things stand

    Read full story

    New ETFs Are Coming to Capitalize On Coronavirus

    Vaxart: Emergent to manufacture Vaxart's experimental COVID-19 vaccine

    Vaxart's stock rises 2.4% premarket, after rocketing 72% on Friday

    Vaxart's stock rockets on heavy volume after initiating coronavirus vaccine development program

    Vaxart's stock soars after upbeat results from oral flu vaccine trial

    • Other News
    • Press Releases

    Better Vaccine Stock: Ocugen or Vaxart?

    on Motley Fool

    Vaxart's Vaccine Candidate Is a Pill, Not a Shot. Does It Matter?

    on Motley Fool

    Vaxart Has 3 Advantages Over Pfizer and Moderna

    on Motley Fool

    Why Vaxart Stock Is Surging Today

    on Motley Fool

    Why Vaxart Shares Popped 78% in April

    on Motley Fool

    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

    on InvestorPlace.com

    VAXART, INC. (VXRT) Reports Q1 Loss, Misses Revenue Estimates

    on Zacks.com

    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

    on InvestorPlace.com

    Why Vaxart Stock Is Soaring Today

    on Motley Fool

    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

    on InvestorPlace.com

    What Will the Stock Market Do Today? 3 Big Stories to Watch.

    on InvestorPlace.com

    VXRT Stock: The Big Vaccine News Sending Vaxart Soaring Today

    on InvestorPlace.com

    Expect Vaxart Stock To Rise on a Unique Approach to Vaccinations

    on InvestorPlace.com

    5 Small-Cap Stocks With 60% to 140% Upside, According to Wall Street

    on Motley Fool

    5 Stocks With 103% to 146% Upside, According to Wall Street

    on Motley Fool

    Should You Buy Vaxart in April?

    on Motley Fool

    These 2 Vaccine Stocks Are Bargains Right Now

    on Motley Fool

    Is the Market For a Flu Vaccine Disappearing?

    on Motley Fool

    These 3 Stocks Will Make You A Fortune If They Succeed

    on Motley Fool

    What Are the Prospects for Vaxart's COVID Vaccine?

    on Motley Fool

    Vaxart Inc.

    Vaxart, Inc. operates as a clinical-stage biotechnology company, which engages in the development of oral recombinant vaccines. Its products include Influenza, Norovirus and Respiratory Syncytial Virus. The company was founded in 2004 and is headquartered in South San Francisco, CA.